ライフサイエンスコーパス: ischemic heart disease

1 age: 68 +/- 12 years; 53.2% had a history of ischemic heart disease).

2 d cardiomyopathy and 21 patients (21.6%) had ischemic heart disease).

3 larizing damaged myocardium in patients with ischemic heart disease.

4 s with acute myocardial infarction or stable ischemic heart disease.

5 of cardiac stem/progenitor cell therapy for ischemic heart disease.

6 tion of PM2.5 with circulatory mortality and ischemic heart disease.

7 also be confirmed in patients suffering from ischemic heart disease.

8 y age, sex, time of symptom onset, and known ischemic heart disease.

9 novel diagnostic and therapeutic targets for ischemic heart disease.

10 lated with QTc prolongation in patients with ischemic heart disease.

11 reducing myocardial injury in subjects with ischemic heart disease.

12 2 could be a potential therapeutic target in ischemic heart disease.

13 onservative strategy in patients with stable ischemic heart disease.

14 clinical workup and therapeutic guidance in ischemic heart disease.

15 ejection fraction not caused by valvular or ischemic heart disease.

16 rophy, cardio-oncology, aortic stenosis, and ischemic heart disease.

17 y and the proportion of adults with baseline ischemic heart disease.

18 ding those presenting early or known to have ischemic heart disease.

19 1941-1994) for mortality from all causes and ischemic heart disease.

20 bral microbleeds, hypertension, diabetes and ischemic heart disease.

21 y for the management of patients with stable ischemic heart disease.

22 se affects almost one-third of patients with ischemic heart disease.

23 poptosis is a significant problem underlying ischemic heart disease.

24 ng the therapeutic potential of AC modRNA in ischemic heart disease.

25 Equal numbers in each group died of ischemic heart disease.

26 saved for each exposed worker who died from ischemic heart disease.

27 ing fluid was recently linked to deaths from ischemic heart disease.

28 -effectiveness of CABG versus PCI for stable ischemic heart disease.

29 0, 5,807) life-years among those who died of ischemic heart disease.

30 edical therapy alone in patients with stable ischemic heart disease.

31 ents who had both type 2 diabetes and stable ischemic heart disease.

32 and ameliorates remodeling in patients with ischemic heart disease.

33 ysis of preclinical data of cell therapy for ischemic heart disease.

34 ticularly high rates of premature death from ischemic heart disease.

35 scular disease but one only half as great on ischemic heart disease.

36 maging immune activity in organs involved in ischemic heart disease.

37 tion report of no association between SU and ischemic heart disease.

38 duced risks of ischemic vascular disease and ischemic heart disease.

39 ve coronary angiography for suspected stable ischemic heart disease.

40 nce on mitral valve geometry and function in ischemic heart disease.

41 ticipants undergoing evaluation for possible ischemic heart disease.

42 revalence/incidence data for each NCD except ischemic heart disease.

43 n is often performed in patients with stable ischemic heart disease.

44 evalence/incidence data for each NCD, except ischemic heart disease.

45 ng that is independent of clinically evident ischemic heart disease.

46 with neither personal nor family history of ischemic heart disease.

47 ally translatable therapeutic strategies for ischemic heart disease.

48 ociation was modified by age, sex, and prior ischemic heart disease.

49 e was 75 years, 73% were female, and 23% had ischemic heart disease.

50 cular contractions (>5000/24 h) and no known ischemic heart disease.

51 iding important diagnostic information about ischemic heart diseases.

52 agnoses (in months) was HF 11.7 (11.6-11.8), ischemic heart disease 1.6 (1.5-1.7), stroke 6.4 (6.3-6.

53 Five-year risk ratios were lower for ischemic heart disease (1.3 [1.3-1.4]), stroke (2.2 [2.1

54 9-1.6), 1.5 (1.2-2.0), and 2.0 (1.4-2.9) for ischemic heart disease; 1.4 (0.9-2.1), 1.2 (0.8-1.9), an

55 analyses revealed a significant increase in ischemic heart disease (10-year hazard ratio, 1.14; 95%

56 litus (+13.1% [95% CI, 10.1-16.0]) but lower ischemic heart disease (-10.6% [95% CI, -13.6 to -7.6])

57 ation was observed in 30.5% of patients with ischemic heart disease: 11.3% had mild airflow limitatio

58 at the 90th and 10th percentile was 2.0 for ischemic heart disease (119.1 vs 235.7 deaths per 100000

59 ercutaneous coronary intervention for stable ischemic heart disease, 1550, 2776, and 6661 received BM

60 South Asians had more ischemic heart disease (+16.5% [95% CI, 14.3-18.6]), hyp

61 ulation, which ranked third in the US behind ischemic heart disease (2447) and low back and neck pain

62 riable odds ratio estimates were as follows: ischemic heart disease 3.30 (95% confidence interval, 2.

63 aths globally between 1990 and 2017 were for ischemic heart disease (3.2 million) and stroke (2.2 mil

64 fold for myocardial infarction, 3.2-fold for ischemic heart disease, 3.2-fold for ischemic stroke, an

65 was responsible for 31% of all deaths, with ischemic heart disease (31%) and cerebrovascular disease

66 mated loss in life expectancy was related to ischemic heart disease (36% in men, 31% in women) but de

67 D as the underlying cause, including chronic ischemic heart disease (42% of CVD deaths), hypertensive

68 it, 1.15; 95% CI, 1.01-1.31; p = 0.041), and ischemic heart disease (7.39; 95% CI, 1.57-34.7; p = 0.0

69 5.6% were women, 23.4% were Black, 53.5% had ischemic heart disease, 87.7% had symptomatic heart fail

70 ary events (myocardial infarction plus fatal ischemic heart disease), 8849 and 10,922 ischemic stroke

71 ubstantial health care spending in 2016 were ischemic heart disease ($89.3 billion [95% CI, $81.1-$95

72 tion fraction who have a lower prevalence of ischemic heart disease, a less severe hemodynamic, bioma

73 We found that ischemic heart disease accounted for only 12% of the com

74 Ischemic heart disease accounted for the second-highest

75 ulant rivaroxaban) for patients with chronic ischemic heart disease, acute coronary syndromes, and th

76 In contrast to patients with ischemic heart disease, after ICD shock HCM patients rar

77 l PM2.5 was associated with a higher risk of ischemic heart disease among aluminum manufacturing work

78 y-related mortality, and higher incidence of ischemic heart disease among PLWHIV in cohort studies) o

79 nd mortality (all-cause, cardiovascular, and ischemic heart disease) among 835 white men in the Norma

80 d concordance statistic of 0.70 and 0.70 for ischemic heart disease and 0.63 and 0.66 for stroke, res

81 ance statistics ranged from 0.66 to 0.67 for ischemic heart disease and 0.68 to 0.72 for stroke.

82 were 0.87 (95% CI: 0.78, 0.97; P = 0.01) for ischemic heart disease and 0.80 (95% CI: 0.73, 0.88; P <

83 was 0.90 (95% CI: 0.75, 1.08; P = 0.27) for ischemic heart disease and 0.88 (0.72, 1.08; P = 0.22) f

84 he equation for prognostic information about ischemic heart disease and all-cause death was evaluated

85 Secondary outcomes included 10-year ischemic heart disease and all-cause death.

86 d vegetables was associated with low risk of ischemic heart disease and all-cause mortality.

87 vegetables, are associated with low risk of ischemic heart disease and all-cause mortality.

88 were 2.5 times and 5.9 times more at risk of ischemic heart disease and cardiomyopathy/heart failure

89 Ischemic heart disease and cerebrovascular disease age-s

90 o adjusted for competing risks of death from ischemic heart disease and death from any cancer], 3.45;

91 Ischemic heart disease and greater age, but not diabetes

92 in myocardium from patients with valvular or ischemic heart disease and heart failure with preserved

93 erapeutic armamentarium in the fight against ischemic heart disease and heart failure.

94 societies, the most common drivers of HF are ischemic heart disease and hypertension.

95 Ischemic heart disease and ischemic stroke comprise the

96 declines in the incidence and mortality from ischemic heart disease and ischemic stroke since the mid

97 e clinical events among patients with stable ischemic heart disease and moderate or severe ischemia.

98 onservative strategy in patients with stable ischemic heart disease and moderate/severe myocardial is

99 al population, mainly because of deaths from ischemic heart disease and other smoking-related disease

100 However, mortality due to ischemic heart disease and other somatic diseases decrea

101 at road traffic noise increases the risk for ischemic heart disease and potentially other cardiometab

102 Patients with stable ischemic heart disease and previous myocardial infarctio

103 risk of adverse outcome after adjustment for ischemic heart disease and QRS width (hazard ratio [HR]:

104 tment in improving survival in patients with ischemic heart disease and reduced ejection fraction.

105 Ischemic heart disease and stroke are the predominant ca

106 rpose We aimed to predict individual risk of ischemic heart disease and stroke in 5-year survivors of

107 Substantial differences exist between county ischemic heart disease and stroke mortality rates.

108 Results Ischemic heart disease and stroke occurred in 265 and 29

109 Ischemic heart disease and stroke remain the leading cau

110 y can predict individual risk for subsequent ischemic heart disease and stroke with reasonable accura

111 through age 50 years for the development of ischemic heart disease and stroke.

112 lence of airflow limitation in patients with ischemic heart disease and the effects on quality of lif

113 ents who had both type 2 diabetes and stable ischemic heart disease and were enrolled in the Bypass A

114 e pathogenesis of common maladies, including ischemic heart diseases and inflammation.

115 f noninvasive modalities in the detection of ischemic heart disease, and discuss nonischemic cardiomy

116 ies (diabetes, hypertension, hyperlipidemia, ischemic heart disease, and glaucoma).

117 y impairment, including sickle cell disease, ischemic heart disease, and heart failure.

118 additional adjustment for diabetes mellitus, ischemic heart disease, and hypertension.

119 hearts is the most comprehensive to date in ischemic heart disease, and its similarities to nonische

120 996 through 2013; with spending on diabetes, ischemic heart disease, and low back and neck pain accou

121 Mortality due to cardiovascular disease, ischemic heart disease, and myocardial infarction.

122 nosis and Management of Patients with Stable Ischemic Heart Disease, and the 2018 European Society of

123 ts with atrial fibrillation, cardiomyopathy, ischemic heart disease, and valvular heart disease.

124 rs, and comorbid conditions of HF (including ischemic heart disease, aortic valve disease, atrial fib

125 Ischemic heart diseases are leading causes of death and

126 Major depressive disorder topped ischemic heart disease as the number one cause of disabi

127 king fluids and mortality, particularly from ischemic heart disease, as well as an instructive exampl

128 ere 45 to 83 years of age and free of HF and ischemic heart disease at baseline.

129 d our ability to understand the pathology of ischemic heart disease, atherosclerosis, and heart failu

130 n the prevalence, symptoms, and prognosis of ischemic heart disease between men and women.

131 ts referred for cardiac CT for evaluation of ischemic heart disease between September 2014 and March

132 ontrol is the cornerstone of managing stable ischemic heart disease but is often not achieved.

133 PCI) relieves angina in patients with stable ischemic heart disease, but clinical trials have not sho

134 centrations are associated with high risk of ischemic heart disease, but whether this is also the cas

135 from all cardiovascular diseases, including ischemic heart disease, cerebrovascular disease, ischemi

136 mortality risks for cardiovascular disease, ischemic heart disease, cerebrovascular disease, or card

137 s, hypertension, dyslipidemia) and diseases (ischemic heart disease, cerebrovascular, and peripheral

138 In addition to ischemic heart disease, certain nonischemic conditions m

139 tial hypertension, coronary atherosclerosis, ischemic heart disease, chronic ischemic heart disease,

140 ent comorbidities, including cardiomyopathy, ischemic heart disease; chronic renal failure, with and

141 zations, whereas 172 suffered from a chronic ischemic heart disease (CIHD), 126 of whom underwent cha

142 The methods are illustrated using data on ischemic heart disease classification, and data from the

143 n patients with hypertrophic cardiomyopathy, ischemic heart disease, diabetes mellitus, and more.

144 ased, including liver disease, hypertension, ischemic heart disease, disorders of lipid metabolism, a

145 Coronary arteries from patients with ischemic heart disease express large amounts of IL-1beta

146 United States who were followed for incident ischemic heart disease from 1998 to 2012, and we address

147 Ischemic heart disease has been relatively uncommon.

148 ic resonance strain imaging in patients with ischemic heart disease have been limited by sample size

149 last few decades, but mortality trends from ischemic heart disease have been more varied, with some

150 cardiac comorbidities in patients with COPD: ischemic heart disease, heart failure, and atrial fibril

151 xamination to identify signs and symptoms of ischemic heart disease, heart failure, and severe valvul

152 morbidity and mortality rates in adults with ischemic heart disease, heart failure, or cardiac surger

153 Among patients with diabetes and stable ischemic heart disease, higher SYNTAX scores predict hig

154 larization is an effective means of treating ischemic heart disease; however, current therapeutic rev

155 by national guidelines in the management of ischemic heart disease; however, few studies have examin

156 lung cancer (HR = 1.08, 95% CI: 1.02, 1.14), ischemic heart disease (HR = 1.09, 95% CI: 1.02, 1.16),

157 3; 95% confidence interval [CI], 1.01-1.06), ischemic heart disease (HR, 1.06; 95% CI, 1.02-1.09), re

158 (HR per 10 ppb, 1.06; 95% CI, 1.04-1.08) and ischemic heart disease (HR, 1.08; 95% CI, 1.05-1.11).

159 ] per 10 mug/m(3), 1.13; 95% CI, 1.08-1.18), ischemic heart disease (HR, 1.16; 95% CI, 1.10-1.23), an

160 ar intake was also inversely associated with ischemic heart disease (HR: 0.56; 95% CI: 0.35 to 0.87)

161 vement in clinical outcomes of patients with ischemic heart disease (IHD) after ventricular tachycard

162 ation to clarify the role of birth weight in ischemic heart disease (IHD) and lipids.

163 Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading

164 However, their long-term risks of ischemic heart disease (IHD) and whether such risks are

165 Background Ischemic heart disease (IHD) has been considered the top

166 The pathogenic role of ischemic heart disease (IHD) in heart failure (HF) with

167 Recognition of ischemic heart disease (IHD) is often delayed or deferre

168 n to cardiovascular disease (CVD) mortality, ischemic heart disease (IHD) mortality, and all-cause mo

169 iations between long-term PM2.5 exposure and ischemic heart disease (IHD) mortality, as established i

170 Ischemic heart disease (IHD) occurred in 62% of patients

171 s in morbidity and mortality attributable to ischemic heart disease (IHD) require an understanding of

172 aise the impact of risk factor confluence on ischemic heart disease (IHD) risk by testing whether gen

173 etween saturated fatty acid (SFA) intake and ischemic heart disease (IHD) risk is debated.

174 Obesity leads to increased ischemic heart disease (IHD) risk, but the risk is thoug

175 e of invasive coronary angiography in stable ischemic heart disease (IHD) varies widely.

176 Previous ischemic heart disease (IHD) was a predictor of in-hospi

177 To clarify the role of thyroid function in ischemic heart disease (IHD) we assessed IHD risk and ri

178 g 7,326 major coronary events (MCEs), 37,992 ischemic heart disease (IHD), and 42,951 strokes were re

179 he pollutants and all-cause, cardiovascular, ischemic heart disease (IHD), and respiratory mortality.

180 Hospital admissions for ischemic heart disease (IHD), congestive heart failure (

181 including myocardial infarction (MI), other ischemic heart disease (IHD), congestive heart failure (

182 isease, previous myocardial infarction (MI), ischemic heart disease (IHD), heart failure (HF), atrial

183 COPD was independently associated with ischemic heart disease (IHD), heart failure (HF), atrial

184 ed estimates of the association of IDO1 with ischemic heart disease (IHD), ischemic stroke and their

185 l hypercholesterolemia (FH) in subjects with ischemic heart disease (IHD), premature IHD, and severe

186 cardiovascular outcomes were CVD [including ischemic heart disease (IHD), stroke, and vascular inter

187 rheumatoid arthritis (RA) is independent of ischemic heart disease (IHD).

188 acids (TFAs) are a well-known risk factor of ischemic heart disease (IHD).

189 s), has been associated with a lower risk of ischemic heart disease (IHD).

190 depression and Alzheimer's disease, but not ischemic heart disease (IHD).

191 red with that in nonstented patients without ischemic heart disease (IHD).

192 ejection fraction overall and in relation to ischemic heart disease (IHD).

193 the prevalence, presentation and outcomes of ischemic heart disease (IHD).

194 vance of animal foods to the pathogenesis of ischemic heart disease (IHD).

195 Ischemic and/or non-ischemic heart diseases (IHD and/or NIHD) were detected

196 ques in coronary arteries from patients with ischemic heart disease implying a role in human arterial

197 Physicians have traditionally viewed ischemic heart disease in a cardiocentric manner: plaque

198 ost frequently identified cause of death was ischemic heart disease in both sexes: 71.7% among women

199 are associated with obesity and the risk of ischemic heart disease in men.

200 mained a significant predictor of asthma and ischemic heart disease in most bipollutant models.

201 sumption is associated with a higher risk of ischemic heart disease in patients with diabetes.

202 ations have been associated with low risk of ischemic heart disease in prospective studies, but resul

203 We will thoroughly review the role of ischemic heart disease in the pathogenesis of HF with re

204 d into 2 documents addressing ACS and stable ischemic heart disease individually.

205 l incidence rate (IR) for each condition are ischemic heart disease, IR=1518.7; myocardial infarction

206 Ischemic heart disease is a complex disease process caus

207 Ischemic heart disease is a leading cause of heart failu

208 Ischemic heart disease is a major cause of out-of-hospit

209 ure with reduced ejection fraction caused by ischemic heart disease is associated with increased morb

210 vascularization improves prognosis in stable ischemic heart disease is controversial.

211 Risk stratification in patients with stable ischemic heart disease is essential to guide treatment d

212 the prevalence of angina and mortality from ischemic heart disease is higher for women than men.

213 Ischemic heart disease is the leading cause of heart fai

214 Ischemic heart disease is the number one cause of death

215 OPD) exacerbations, pneumonias, lung cancer, ischemic heart disease, ischemic stroke, and all-cause m

216 Its major clinical manifestations include ischemic heart disease, ischemic stroke, and peripheral

217 e risk of first fatal or nonfatal CVD event (ischemic heart disease, ischemic stroke, heart failure,

218 Heart samples from ischemic heart disease (ISHD) patients served as heart f

219 dalities for the diagnosis and management of ischemic heart disease, it is important for radiologists

220 condition categories (eg, diabetes mellitus, ischemic heart disease, liver disease).

221 to be younger, men, have diabetes mellitus, ischemic heart disease, lower left ventricular ejection

222 ed cardiovascular care for the management of ischemic heart disease may not be infected with this nov

223 roups including patients with versus without ischemic heart disease, men versus women, those aged <75

224 vative strategy) in participants with stable ischemic heart disease, moderate or severe ischemia, and

225 Participants with stable ischemic heart disease, moderate or severe ischemia, and

226 1.1%-3.6%) and 6.9% (95% CI, 4.0%-9.9%) for ischemic heart disease mortality among adults 65 years a

227 Ischemic heart disease mortality and long-term exposure

228 The association between coal use and ischemic heart disease mortality diminished with increas

229 An overall trend for reduction in ischemic heart disease mortality was observed, most pron

230 86, 4.68) for all-cause, cardiovascular, and ischemic heart disease mortality, respectively.

231 men compared with men, with similar risk for ischemic heart disease mortality.

232 Mortality rates (MRs) for each condition are ischemic heart disease, MR=105.5; ischemic stroke, MR=42

233 rosclerosis, ischemic heart disease, chronic ischemic heart disease, myocardial infarction, and hyper

234 Twenty sepsis patients, 11 ischemic heart disease, nine dilated cardiomyopathy, and

235 s between ingestion of inorganic arsenic and ischemic heart disease, nonmalignant respiratory disease

236 Ischemic heart disease (odds ratio [OR], 7.21; P < 0.001

237 HF was higher in patients with a history of ischemic heart disease or atrial fibrillation.

238 age, 67+/-11.6 years; 88 men) with suspected ischemic heart disease or known coronary disease who had

239 altered abundance in septic cardiomyopathy, ischemic heart disease, or dilated cardiomyopathy, in co

240 did not differ according to age, race, prior ischemic heart disease, or ejection fraction (all intera

241 and the coexistence of atrial fibrillation, ischemic heart disease, or hypertensive cardiopathy.

242 defined as a history of atrial fibrillation, ischemic heart diseases, or congestive heart failure.

243 cancer (HR = 1.14; 95% CI: 1.03, 1.27), and ischemic heart disease (overall HR = 1.61; 95% CI: 1.14,

244 EBW occurred most often in ischemic heart disease patients (N=114, 49%) compared wi

245 R 0.33, 95% CI 0.14 to 0.80, p = 0.010), and ischemic heart disease (POR 0.46, 95% CI 0.29 to 0.73, p

246 e for HIV and the presence of a cough, COPD, ischemic heart disease, pregnancy-related mortality, mat

247 Ischemic heart disease prevalence increased for all to 2

248 genetic variants near IRF2BP2 associate with ischemic heart disease progression in humans.

249 Patients with stable ischemic heart disease remain at substantial risk for lo

250 Ischemic heart disease remains rare in most countries.

251 Ischemic heart disease remains the foremost cause of dea

252 y syndrome (ACS), the acute manifestation of ischemic heart disease, remains a major cause of morbidi

253 Ischemic heart disease resulting from myocardial infarct

254 In patients with stable ischemic heart disease, routine revascularization was no

255 (rate ratio [RR], 1.14; 95% CI, 1.13-1.14), ischemic heart disease (RR, 1.11; 95% CI, 1.10-1.11), ma

256 (rate ratio [RR], 1.62; 95% CI, 1.20-21.8), ischemic heart disease (RR, 4.31; 95% CI, 3.38-5.49), an

257 ), asthma (RR=1.12, 95% CI: 1.03, 1.22), and ischemic heart disease (RR=1.19, 95% CI: 1.03, 1.38).

258 Autologous and allogeneic cell therapy for ischemic heart disease show a similar improvement in lef

259 prediction model including QRS duration and ischemic heart disease significantly improved the net re

260 -world population among subjects with stable ischemic heart disease (SIHD) and acute coronary syndrom

261 sk factor management in patients with stable ischemic heart disease (SIHD) and diabetes mellitus (DM)

262 ve (FFR) measurement in patients with stable ischemic heart disease (SIHD) are uncertain, as prior st

263 Stable ischemic heart disease (SIHD) is a leading cause of deat

264 All patients with stable ischemic heart disease (SIHD) should be managed with gui

265 ularization strategy in patients with stable ischemic heart disease (SIHD) who have type 2 diabetes (

266 long-term prognosis in patients with stable ischemic heart disease (SIHD).

267 atures such as age, history of arrhythmia or ischemic heart disease, size of goiter, and severity of

268 Cardiovascular diseases (CVDs), including ischemic heart disease, stroke, and heart failure, are w

269 10 dietary factors accounts for 18.2% of all ischemic heart disease, stroke, and type 2 diabetes cost

270 years associated with the development of HF, ischemic heart disease, stroke, peripheral artery diseas

271 rtension, diabetes mellitus, hyperlipidemia, ischemic heart disease, stroke, total cholesterol level,

272 ween acute myocardial Infarction and chronic ischemic heart disease subgroups.

273 More people die every year from ischemic heart disease than any other disease.

274 in patients with congestive heart failure or ischemic heart disease than in those without (P = 0.021

275 nosis and Management of Patients with Stable Ischemic Heart Disease, the 2014 Focused Update of the A

276 ts with systolic heart failure not caused by ischemic heart disease, the association between the ICD

277 TSD) is associated with an increased risk of ischemic heart disease, though the pathophysiologic mech

278 ogenic precursors link coronary anomalies to ischemic heart disease.Though coronary arteries are cruc

279 randomly assigned 2287 patients with stable ischemic heart disease to an initial management strategy

280 phases of the disease, potentially allowing ischemic heart disease to be tracked during a patient's

281 t they might be used in patients with stable ischemic heart disease to identify those at high risk fo

282 , including individual data of patients with ischemic heart disease treated with cell therapy.

283 ty of mitral regurgitation, 67 patients with ischemic heart disease underwent cardiac magnetic resona

284 med stress score <3 and without a history of ischemic heart disease), valvular, and end-organ disease

285 rtality ratios and absolute excess risks for ischemic heart disease, valvular heart disease, and card

286 ar disease such as congestive heart failure, ischemic heart disease, valvular heart disease, pulmonar

287 Mortality from ischemic heart disease was lower among former players th

288 Ischemic heart disease was present in 72% of patients.

289 ntative sample of 50 patients with suspected ischemic heart disease was retrospectively selected from

290 cells in immunosuppressed animals with acute ischemic heart disease, we previously showed that these

291 y, peripheral neuropathy, diabetic foot, and ischemic heart disease were 21.9%, 17.6%, 28.0%, 6.2%, a

292 creatinine level, black race, older age, and ischemic heart disease were associated with troponin ele

293 in acute coronary syndromes (ACS) and stable ischemic heart disease were combined into 1 document.

294 , nonshockable rhythm, arterial lactate, and ischemic heart disease were identified as independent pr

295 tissue samples from patients suffering from ischemic heart disease were used to validate our finding

296 d exertional E/e' >13), excluding those with ischemic heart disease, were recruited in a tertiary car

297 Among the 3,103 patients with ischemic heart disease who were recruited, lung function

298 significant in the pathophysiology of human ischemic heart disease with a preservative role in maint

299 ted myocardium, even in patients with stable ischemic heart disease with preserved LV ejection fracti

300 dox is an observation of a low prevalence of ischemic heart disease, with high intakes of saturated f